Recombinant Human IL6 Protein (HE0120IL)

Cat.No.

HE0120IL

Synonyms

IL6; IFNB2; BSF2; HGF; HSF; IL 6; CDF; BSF-2; IFN-beta-2; IL-6;

Species

Human

Accession

IL6

Source

E. coli

Predicted N Terminal

Met

Form

Lyophilized from sterile PBS, pH 7.4, 5 % trehalose and 5 % mannitol.

Bio-activity

Measured by its binding ability in a functional ELISA. Immobilized recombinant human IL-6 at 8 μg/ml (100 μl/well) can bind recombinant human IL6R with a linear range of 1.25-20.0 ng/mL. Measured in a cell proliferation assay using TF-1 human erythroleuke

Molecular Mass

Recombinant Human IL6 consists of 184 amino acids and migRates with an apparent molecular mass of 20.3 kDa as estimated in SDS-PAGE under reducing conditions.

Endotoxin

< 1.0 EU per 1 microgram of protein (determined by LAL method).

Purity

> 95 % by SDS-PAGE.

Background

Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an "alarmin", that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528). In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets (PubMed:21734074). This form is rapidely lost upon angiogenic or proinflammatory activation (PubMed:18787100).